Cost effectiveness and cost utility analyses of finasteride therapy for the treatment of benign prostatic hyperplasia - systematic review
Baladi JF, Menon D
Record ID 31996008284
English, French
Authors' objectives:
To examine the cost-effectiveness of finasteride therapy in the treatment of benign prostatic hyperplasia in Canadian provinces.
Authors' results and conclusions:
Finasteride has a place in the management of benign prostatic hyperplasia. In patients with moderate symptoms, if offers increased health related quality of life compared to watchful waiting or TURP, but at a cost to the health care system.
Authors' recommendations:
There is an economic/clinical argument for including finasteride in provincial drug plan formularies for a specific category of patient defined by its symptom severity and the time horizon involved in the drug therapy.
Details
Project Status:
Completed
URL for project:
https://www.ccohta.ca/
Year Published:
1995
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Decision Support Techniques
- Finasteride
- Prostatic Hyperplasia
Contact
Organisation Name:
Canadian Coordinating Office for Health Technology Assessment
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Coordinating Office for Health Technology Assessment
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.